

**RESTRICTION REQUIREMENT**

Claims 1, 7-14, 16-27, 29-38, and 40-45 are currently pending in the application. Claim 13 has been amended herein. No new matter has been added.

The Examiner has required election of one of the following four groups under 35 U.S.C. §§ 121 and 372:

- I. Claim(s) 1, 7-14, 16-23 and 41-45, drawn to a pharmaceutical composition containing a fusion protein of a *Mycobacterium tuberculosis* molecular chaperon DnaK protein, a signal peptide and a HPV E7 or E6 protein.
- II. Claim(s) 24-36, drawn to a method of inducing an antigen specific immune response in a subject by administering Group 1.
- III. Claim(s) 37, 38 and 40, drawn to a method of inhibiting growth or preventing regrowth of a tumor expressing HPV E7 or E6 by administering Group 1.

In response to the Restriction Requirement, Applicants hereby elect, **Group I**, without traverse. Applicants respectfully submit that claims 1, 7-14, 16-23, and 41-45, are readable on the elected group.

The Examiner has further required a species election of a specific combination of (a) a specific nucleic acid sequence from “(a)” or the C-terminal domain of (iii), as stated in claim 1 and (b) a specific third nucleic acid sequence point of origin (see line 4 of part (c)), as stated in claim 1. In response, Applicants respectfully elect **(a) the C-terminal domain of SEQ ID NO: 10 and (b) HPV-16 E7 polypeptide of SEQ ID NO: 2 having a substitution of Gly or Ala in the place of Cys at position 24**. Applicants respectfully submit that claims 1, 7-14, 16-23, and 41-45 are readable upon the elected species.

Applicants expressly reserve the right to prosecute non-elected claims and species in other patent applications claiming the benefit of the filing date of this application. Furthermore, Applicants understand that upon allowance of a claim to the elected invention, they will be entitled to consideration of the nonelected inventions for rejoinder, as well as claims to additional species which are written in dependent form or otherwise include all the limitations of any allowed generic claims.

**CONCLUSION**

Early and favorable consideration of the application is respectfully solicited. If a telephone conversation with Applicant's attorney would expedite prosecution of the above-identified application, the Examiner is invited to call the undersigned at (617) 832-1000. Please charge any additional fees required to enter this response, or credit any overpayment, to **Deposit Account No. 06-1448, Reference JHV-050.01**.

Dated: November 22, 2010

Respectfully submitted,

By Hathaway P. Russell/

Hathaway P. Russell

Registration No.: 46,488

FOLEY HOAG LLP

155 Seaport Blvd

Boston, Massachusetts 02210

(617) 832-1000

Attorney for Applicants